Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
The Oncologist
|
November 26, 2024
Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic
Alessandro Parisi, Riccardo Giampieri, Silvia Villani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2022
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
Florian Kocher, Alberto Puccini, Gerold Untergasser, et al.
Targeted Oncology
|
March 28, 2018
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study
Maria Di Bartolomeo, Monica Niger, Giuseppe Tirino, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 8, 2024
An international survey on the knowledge, attitudes and clinical patterns of use of medical cannabis for cancer care: The TASMAN study
Dario Trapani, Sara J Nidhamalddin, Sara Gandini, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 15, 2021
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Paolo Antonetti, Maria Concetta Fargnoli, Giampiero Porzio, et al.
Frontiers in Oncology
|
August 29, 2022
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis
Alessandro Parisi, Riccardo Giampieri, Alex Mammarella, et al.
Frontiers in Oncology
|
November 15, 2021
Post-Induction Management in Patients With Left-Sided <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
Alessandro Parisi, Alessio Cortellini, Olga Venditti, et al.
Clinical Colorectal Cancer
|
August 12, 2021
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study
Alessandro Parisi, Giampiero Porzio, Katia Cannita, et al.
Nature Medicine
|
March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
Joris van de Haar, Xuhui Ma, Salo N Ooft, et al.
JAMA Oncology
|
July 10, 2025
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Alessandro Audisio, Chiara Gallio, Vaneja Velenik, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
The Oncologist
|
November 26, 2024
Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic
Alessandro Parisi, Riccardo Giampieri, Silvia Villani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2022
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
Florian Kocher, Alberto Puccini, Gerold Untergasser, et al.
Targeted Oncology
|
March 28, 2018
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study
Maria Di Bartolomeo, Monica Niger, Giuseppe Tirino, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 8, 2024
An international survey on the knowledge, attitudes and clinical patterns of use of medical cannabis for cancer care: The TASMAN study
Dario Trapani, Sara J Nidhamalddin, Sara Gandini, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 15, 2021
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Paolo Antonetti, Maria Concetta Fargnoli, Giampiero Porzio, et al.
Frontiers in Oncology
|
August 29, 2022
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis
Alessandro Parisi, Riccardo Giampieri, Alex Mammarella, et al.
Frontiers in Oncology
|
November 15, 2021
Post-Induction Management in Patients With Left-Sided <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
Alessandro Parisi, Alessio Cortellini, Olga Venditti, et al.
Clinical Colorectal Cancer
|
August 12, 2021
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study
Alessandro Parisi, Giampiero Porzio, Katia Cannita, et al.
Nature Medicine
|
March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
Joris van de Haar, Xuhui Ma, Salo N Ooft, et al.
JAMA Oncology
|
July 10, 2025
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Alessandro Audisio, Chiara Gallio, Vaneja Velenik, et al.
Page
of 7